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Disease name corpusInformation encoded in natural language in biomedical literature publications is only useful if efﬁcient
and reliable ways of accessing and analyzing that information are available. Natural language processing
and text mining tools are therefore essential for extracting valuable information, however, the develop-
ment of powerful, highly effective tools to automatically detect central biomedical concepts such as dis-
eases is conditional on the availability of annotated corpora.
This paper presents the disease name and concept annotations of the NCBI disease corpus, a collection
of 793 PubMed abstracts fully annotated at the mention and concept level to serve as a research resource
for the biomedical natural language processing community. Each PubMed abstract was manually anno-
tated by two annotators with disease mentions and their corresponding concepts in Medical Subject
Headings (MeSH) or Online Mendelian Inheritance in Man (OMIM). Manual curation was performed
using PubTator, which allowed the use of pre-annotations as a pre-step to manual annotations. Fourteen
annotators were randomly paired and differing annotations were discussed for reaching a consensus in
two annotation phases. In this setting, a high inter-annotator agreement was observed. Finally, all results
were checked against annotations of the rest of the corpus to assure corpus-wide consistency.
The public release of the NCBI disease corpus contains 6892 disease mentions, which are mapped to
790 unique disease concepts. Of these, 88% link to a MeSH identiﬁer, while the rest contain an OMIM
identiﬁer. We were able to link 91% of the mentions to a single disease concept, while the rest are
described as a combination of concepts. In order to help researchers use the corpus to design and test
disease identiﬁcation methods, we have prepared the corpus as training, testing and development sets.
To demonstrate its utility, we conducted a benchmarking experiment where we compared three different
knowledge-based disease normalization methods with a best performance in F-measure of 63.7%. These
results show that the NCBI disease corpus has the potential to signiﬁcantly improve the state-of-the-art
in disease name recognition and normalization research, by providing a high-quality gold standard thus
enabling the development of machine-learning based approaches for such tasks.
The NCBI disease corpus, guidelines and other associated resources are available at: http://
www.ncbi.nlm.nih.gov/CBBresearch/Dogan/DISEASE/.
Published by Elsevier Inc. Open access under CC BY-NC-SA license. 1. Background
1.1. The importance of disease name recognition for biomedical
research
Disease is one of the fundamental biological entities in biomed-
ical research, one of main research goals at the National Institutes
of Health, and as a result, it is frequently searched for in literature
[1] and on the Internet [2]. Hence, like other named entity recogni-tion tasks and similar to gene name identiﬁcation [3,4], disease
name recognition is an important task in biomedical text mining
and plays a critical role in accelerating scientiﬁc discovery and con-
tributing to improved information access [5].
Automatic disease recognition from free text is a challenging
task due to both variation and ambiguity in disease names, as well
as its deﬁnition (e.g., is fever a disease?) [5,6]. From a taxonomic
system point of view – there is signiﬁcant ambiguity in what is a
disease name: adenomatous polyposis coli and Friedrich ataxia can
be both gene and disease names. Abbreviated disease names are
common in biomedical literature, and the same abbreviation may
stand for many different diseases. For example, AS may stand for
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syndrome, autism spectrum, etc. Lastly, while it is extremely
important to allow doctors and health practitioners the freedom
to effectively describe a disease by use of descriptive expressions,
this poses a higher level of difﬁculty for applying automatic iden-
tiﬁcation methods to medical text [7,8].
Current disease name entity recognition methods generally
contain two separate steps: disease mention recognition, followed
by disease concept recognition, i.e., the grounding of the pre-iden-
tiﬁed disease mentions to corresponding standard database identi-
ﬁers [6,9]. The second step, concept recognition (also known as
normalization), is crucial for specifying the diseases mentioned in
text. A PubMed article may reference the same disease concept
multiple times, possibly using variations of one or more of its ac-
cepted full terms (long form) and also abbreviations (short forms).
After normalization, unique disease concepts can be further used
for a number of downstream analyses: Providing users with the
ability to ﬁnd a more relevant subset of resources based on user
queries; allowing for detecting unique associations between dis-
eases and genes in the literature; etc.
Previous studies on automatic disease mention recognition
show that machine-learning based approaches [10,11] compare
favorably to dictionary lookup or rule-based methods. However,
to our best knowledge, most approaches on disease normalization
are knowledge-based as opposed to learning-based [12,13], which
is related to the lack of sufﬁcient gold-standard training data. We
also note that fewer attempts to recognize disease names have
been reported compared to the large body of work on gene normal-
ization studies, such as [14–16].
1.2. Constructing high-quality corpora for disease name recognition
Manually annotated high-quality corpora are of utmost impor-
tance for the development of sophisticated NLP systems, both as
training data and for evaluative purposes. Manually annotated bio-
medical corpora have consistently made possible the achievement
of improved results in biomedical NLP research, with impressive re-
sults being observed in tokenization tasks [17], part-of-speech iden-
tiﬁcation tasks [18,19], clinical concept identiﬁcation tasks [20], etc.
To assist the development and evaluation of the disease name
recognition task, we have developed a disease corpus, namely
the NCBI disease corpus. The construction of the NCBI disease cor-
pus went through two major phases: mention-level annotation
and concept-level annotation. As a result, the NCBI disease corpus
was manually annotated for every disease mention and its corre-
sponding concept for a total of 793 PubMed abstracts. The men-
tion-level annotation work has been described in [21]. In a
nutshell, disease mentions were annotated based on their rele-
vance for biomedical information retrieval tasks that involve dis-
eases. Annotation guidelines allowed ﬂexible matching to UMLS
concepts and categorized four annotation categories: Composite
mentions, Modiﬁers, Disease Class mentions and Speciﬁc Diseases.
The corpus was reviewed several times by several annotators and
when used as gold-standard data for a state-of-the-art machine
learning system, it was able to signiﬁcantly improve its performance
for disease name recognition [21]. The second phase was the con-
cept-level annotation which completes the NCBI disease corpus as
a disease name recognition resource, and releases it to the commu-
nity in its complete form. The completed NCBI disease corpus has al-
ready enabled the creation and evaluation of the ﬁrst machine
learning method for disease normalization, DNorm, which relies
on the joint mention-level and concept-level annotations of the cor-
pus to learn term variations directly from the training data [22].
The objective of our work is not only to facilitate information
retrieval tasks that involve diseases, but also to facilitate future
applications of complex information retrieval tasks connectingdiseases to treatments, causes or other types of information,
speciﬁcally for biomedical literature. Hence, the next important
step towards this goal is the entity normalization task that involves
mapping mentions to standard database/ontology identiﬁers. In
the present paper, we present our work on developing the NCBI
disease corpus to map the individual disease mentions to standard
disease controlled vocabularies, namely MeSH (http://www.nlm.
nih.gov/mesh/) and OMIM (http://www.ncbi.nlm.nih. gov/omim)
identiﬁers.
Finding a vocabulary for capturing disease data is a very impor-
tant decision. We wanted a disease vocabulary that was reliable,
publicly available, relatively stable, regularly maintained, and suit-
able for indexing biomedical literature. We were looking for a
vocabulary source that was previously used and would naturally
be used in the future as an annotation source for biomedical text
in order to facilitate interoperability. We focused on MeSH ‘Dis-
eases’ branch, and added the speciﬁcity of OMIM identiﬁers for ge-
netic diseases, as practically combined in MEDIC, the MErged
DIsease voCabulary [23]. In essence, MEDIC is a combination of
the MeSH ‘disease’ branch and OMIM such that it is both deep
and broad (we downloaded MEDIC on April 17, 2012, which con-
tained 9661 disease concepts, and about 67,000 terms). It also con-
tains signiﬁcantly fewer concepts/terms compared to the UMLS
Metathesaurus [24], which makes it more convenient for real-life
manual curation.
1.3. NCBI disease corpus for disease name recognition
The work to develop the NCBI disease corpus is closely related
to several other corpus construction efforts in the biomedical do-
main [25–34]. These studies speciﬁcally agree on: 1. the need for
multiple experienced annotators; 2. the need for detailed annota-
tion guidelines; and 3. the need for large scale high-quality anno-
tation corpora. The NCBI disease corpus fulﬁlls all these needs
and constitutes therefore a signiﬁcant resource for disease name
entity recognition research in biomedical text.
The NCBI disease corpus also is not the ﬁrst resource for disease
entity recognition in biomedical research. This corpus signiﬁcantly
extends two existing disease corpora [11,13]. Major differences be-
tween the new corpus and the two previous corpora include three
aspects (shown in Table 1). First, all sentences in an abstract are se-
lected for annotation in the NCBI disease corpus, which is impor-
tant to enable higher level text mining tasks that explore
relationships between diseases and other types of entities such
as genes or drugs in the same abstract. As a result, the NCBI disease
corpus is also several times larger than the existing corpora. Sec-
ond, a novel aspect of our concept annotation lies in the use of
the recently developed MEDIC vocabulary for assigning disease
concepts [23]. Finally, unlike the annotations in the two previous
corpora, each annotation in our corpus was completed by at least
two individuals. We believe having multiple annotations helps en-
sure higher quality results: both more objective and fewer missing
ones, which have been recently noted as an issue by researchers
developing a disease normalization system [35].
The contributions of this article are: 1. A comprehensive descrip-
tion of the annotation process for constructing the NCBI disease cor-
pus, 2. A thorough exploration of the NCBI disease corpus and its
characteristics, 3. An introduction of the NCBI disease corpus as a
resource setup to build and evaluate new disease name recognition
methods, 4. An initial evaluation of three different disease recogni-
tion models and their description, 5. An analysis of the results and
future directions for improvement, and ﬁnally and most impor-
tantly and 6. The public release of the NCBI disease corpus to the
biomedical community for further use and research. The rest of
the article is organized as follows: In Section 2 we describe the cor-
pus and tools used to perform the annotation task, the annotation
Table 1
Characteristics of disease corpora.
Disease
corpus
Corpus size Disease
mention
Disease
concept
ontology
Number of
annotators
Jimeno
et al.
[13]
856 selected
sentences in 642
abstracts
No UMLS 2
Leaman
et al.
[11]
2783 selected
sentences in 793
abstracts
Yes UMLS 1
NCBI
disease
corpus
All 6881 sentences in
793 abstracts
Yes MEDIC 14
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the procedure to ensure the quality of resulting annotations. Further-
more, we follow by a description of the three disease name recogni-
tionmethods that were used to identify disease concepts in the NCBI
disease corpus. Section 3 lists the inter-annotator agreement results,
details and summarizes the NCBI disease corpus characteristics, and
then explores and compares the results of three different approaches
for disease name recognition on the NCBI disease corpus. In the next
section, we discuss the choice of the terminology resource, advanta-
ges, disadvantages and limitations of preferring one terminology
resource as opposed to others, the challenges of disease name
normalization as opposed to other related tasks such as gene name
normalization, speciﬁcally how these all relate to the NCBI disease
corpus, and lastly, we give our concluding remarks in Section 5.2. Methods
2.1. Data sources and preparation
The annotation work on the NCBI disease corpus was performed
in two stages, where annotators worked both individually and in
pairs to rectify differences in annotation and ensure the construc-
tion of a high-quality product. At the beginning, annotators were
also provided help in the form of pre-annotations and an easy-
to-use web-based annotation tool PubTator [35,36], whose versa-
tility in biomedical concept annotation has been demonstrated in
the recent BioCreative tasks. The ﬁrst stage took place in summer
2011 when a group of 12 annotators each annotated an average
of 125 PubMed documents, so that for each document we had at
least two annotators. This work resulted in a completely annotated
disease mentions corpus [21]. Disease mentions were categorized
in four categories: Speciﬁc Disease or Disease Class, (i.e., <Speciﬁc
Disease> Diastrophic dysplasia </> is an <Disease Class> autosomal
recessive disease </> characterized by. . ..) or Composite Mention
(i.e., <CompositeMention> Combined genetic deﬁciency of C6 and
C7 </> in man) or Modiﬁer (i.e., The Israeli <Modiﬁer> C7-deﬁcient
</> cases all share a C7 haplotype. . ..). The second stage took place
in summer 2012 when a group of 14 annotators (10 overlapped
with the ﬁrst group) annotated 120 PubMed documents each on
average, so that for each citation we had at least two annotators.
This work improved consistency of the mention level annotations,
and added the normalization layer of annotations, so that each dis-
ease mention in text is linked to a standardized medical vocabulary
entry, namely a MeSH descriptor or OMIM identiﬁer, as listed in
the MEDIC vocabulary.2.1.1. Annotators and the pre-annotation process
The annotator group consisted of 14 people with backgrounds
in biomedical informatics research and experience in biomedical
text corpus annotation. The 793 PubMed citations were divided
into sets of 30 PubMed citations each. Every annotator workedon 4 or 5 sets of 30 PubMed abstracts. The sets were divided ran-
domly among annotators such that each set was shared by at least
two people. To avoid annotator bias, pairs of annotators were cho-
sen randomly for each set, so that each pair of annotators over-
lapped for at most two sets.
According to our own experience [27,36] and others [37], auto-
matic pre-annotation can help accelerate the manual annotation
process. First, each PMID document was pre-annotated using the
Inference Method developed for disease name normalization [9],
which properly handles abbreviation recognition, robust string
matching, etc. As such, human annotators were given the pre-
annotated documents as a starting point and allowed to see each
pre-annotation with a computed conﬁdence. Annotators were also
told about the limitations of the automatic method, such as incom-
plete results for composite disease mentions.
2.1.2. Annotation guidelines
For disease concept annotation, annotators were encouraged to
use their domain knowledge, as well as any other public resources
such as UMLS and Wikipedia. Initially, a set of 20 randomly chosen
PubMed abstracts was used as a practice set for the development of
annotation guidelines. After each annotator worked individually on
the set, the results were shared and discussed among all annota-
tors. The ﬁnal annotation guidelines are summarized below and
also made available at the corpus download website.
To explain our annotation rules, we use the disease mentions in
the following text (bolded) as a running example: ‘‘The Schwartz-
Jampel syndrome (SJS) is a recessively inherited condition de-
ﬁned by myotonia, short stature, and bone dysplasia.’’
1. Annotate the concept that matches the preferred name.
There are several matches for ‘‘myotonia’’ in MEDIC: Myo-
tonia [MESH:D009222], Myotonia Congenita
[MESH:D009224], Myotonic Disorders [MESH:D020967],
Myotonic Dystrophy [MESH:D009223], etc. For the men-
tion ‘‘myotonia’’, the entry MESH:D009222 is selected
because it provides a perfect match to this concept’s pre-
ferred name. Moreover, the descriptions of the other pos-
sible matches do not provide a better ﬁt when taking
into account the context of the article.2. Annotate the concept that matches the synonym name,
unless there is another concept that matches the preferred
name.
Several MEDIC entries may match the mention ‘‘bone dys-
plasia’’: Bone Diseases, Developmental [MESH:D001848],
Gracile bone dysplasia [MESH:C537291], Fibrous Dyspla-
sia of Bone [MESH:D005357], etc. For the mention ‘‘bone
dysplasia’’, the entry MESH:D001848 is selected because
it lists a synonymwhich is a perfect match to this mention.3. Annotate the most speciﬁc concept that correctly describes
the disease mention. Certain disease concepts in MeSH are
disease classes, which are described with a MeSH entry
term and several synonymous terms corresponding to the
speciﬁc disease names within that class. In such cases,
MEDIC lists the correct MeSH ID for the concept as well
as a secondary list of OMIM identiﬁers for the speciﬁc dis-
eases within that class. For example, the MEDIC entry for
‘‘Schwartz-Jampel syndrome’’ is Osteochondrodysplasias
[MeSH: D010009], with a secondary list of speciﬁc identiﬁ-
ers: OMIM:239100, 255800, and 309350. The disease ‘‘Sch-
wartz-Jampel syndrome’’ is a synonym for the MeSH entry
D010009. A closer consideration of the list of OMIM identi-
ﬁers reveals that OMIM:239100 corresponds to Van
Buchem Disease, OMIM:255800 to Schwartz-Jampel syn-
drome, and OMIM:30930 to Melnick-Needles Syndrome,
which are all synonyms of the MeSH entry term Osteo-
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pel syndrome’’, the entry OMIM:255800 is selected as the
normalized concept because it is the disease concept that
correctly describes the mention. In the cases where MEDIC
lists one MeSH descriptor and one OMIM identiﬁer, these
two identiﬁers are considered equivalent; therefore either
one can be selected.
4. Annotate the closest hypernym concept that logically
describes the disease mention.
Certain disease mentions in text are hard to map to a dis-
ease concept in the dictionary. For example, a search in
MEDIC for ‘‘recessively inherited condition’’ produces
no results and other sophisticated string matching
approaches report unrelated results. The mention ‘‘reces-
sively inherited condition’’ though, is annotated as a dis-
ease name in our corpus, and the entry Genetic Diseases,
Inborn [MeSH:D030342] is chosen as the correct normali-
zation because it provides the closest hypernym logical
concept that correctly describes the disease mention. In
this case however, MeSH is not speciﬁc enough and does
not distinguish inherited diseases as dominant versus
recessive, so a less speciﬁc mapping is produced. We dis-
cuss these cases further in the Discussion session.5. Annotate all concepts in a composite disease mention
using the ‘‘|’’ separator.
Composite mentions such as: ‘‘colorectal, endometrial,
and ovarian cancers’’ can be normalized to the collection
of the individual constituents MeSH:
D010051|D016889|D015179. The ‘‘|’’ character is used to
compose this mapping, and this signals the presence of a
composite mapping.6. Annotate a disease mention using multiple concepts to
logically describe the disease mention, using the ‘‘+’’
concatenator.
In rare cases, representing a disease mention may require
multiple concepts. For example, a mapping can be pro-
duced between the mention ‘‘inherited neuromuscular
disease’’ and the concept Neuromuscular Disease
[MeSH:D009468]. However, the MeSH entry description
of D009468 does not imply that these diseases are inher-
ited. Hence, a combination of identiﬁers: Neuromuscular
Disease [MeSH:D009468] + Genetic Diseases, Inborn
[MeSH:D030342] is a better concept normalization for
that mention. The ‘‘+’’ character is used to compose this
mapping, and this signals the presence of a multiple con-
cept mapping, not to be confused with a composite
mapping.7. Annotate a disease mention even if that mention is used
interchangeably as a gene name.
If the same mention is used as both a disease name and a
gene name, therefore introducing a gene name – disease
name ambiguity, then the mention is considered a disease
name mention. This particular guideline was motivated by
the fact that we wanted to be thorough in our annotation
process, and annotate every textual mention that referred
to a disease. This meant that sometimes the disease men-
tion was not a noun phrase but a modiﬁer (disease anno-
tation tag: Modiﬁer). A typical example would be: ‘‘. . .
the <Modiﬁer> VHL </Modiﬁer> gene. . .’’. The ambiguous
mention is annotated and normalized to the VHL disease
name concept; because VHL is a recognized synonym for
the disease term Von Hippel-Lindau, and the phrase
‘‘VHL gene’’ is interpreted as ‘‘the gene causing the disease
VHL’’.8. When necessary, use speciﬁc concepts in OMIM not
included in MEDIC.It is possible that a disease mention may not be covered in
MEDIC. This was experienced by our annotators a handful
of times. For these cases,we adopted the following solution:
if OMIM contained a concept that described that disease
mention, we used this identiﬁer accordingly. For example:
Leptin deﬁciency [OMIM:164160] and Complement Com-
ponent 9 deﬁciency [OMIM:613825] are annotated in our
corpus although they were not included in the Spring
2012 version of MEDIC that was used for this work.2.1.3. Annotation process and the annotator software
Similar to the steps in disease mention annotation [21] the
annotation of disease concepts was also organized in consecutive
phases and used PubTator [36,38] as the web-based annotation
tool. Phase I consisted of each pre-annotated abstract in the corpus
being read and reviewed by two annotators working indepen-
dently. Annotators could agree with the pre-annotation, remove
it, or modify it. Annotators could also add new mappings. The
annotation software automatically updated duplicated mentions
within the same document, thus ensuring consistency of annota-
tions within each document. After this round of independent anno-
tation, a summary document was created highlighting the
agreement and differences between annotators. Accordingly, in-
ter-annotator agreement was calculated at this step and it is re-
ported in Section 3.
In Phase II, each annotator examined and edited his or her own
annotations by reviewing the differences reported in the Phase I
summary. The annotation software allowed that each annotator
to compare their results for each set with those of other annotators
that worked on the same set. Visual cues were implemented to sig-
nal agreement and disagreement between annotators at two gran-
ularity levels: PMID document level and PMID annotation set level.
At the PMID document level, as illustrated in Fig. 1, the annotator
sees the title and abstract of the document,with the highlighted dis-
ease mentions. Below the text box, a table of all mentions is pro-
duced contrasting the annotations between annotators. Each
annotator may see the others’ selections, but can only edit his/her
own work. To facilitate the review process, this view also allows
for one-click access to the MEDIC records of the normalized con-
cepts. At the PMID annotation set level, not shown, each annotator
sees the list of PMID titles of the shared annotation set. For each Pub-
Med citation, if all annotators agree on all annotations, then that
citation is highlighted in the summary view, to signal agreement.
After this round, an additional summary similar to that of Phase I
was generated to highlight the remaining differences after Phase II.
Then, each pair of annotators organized meetings where they dis-
cussed and resolved their differences. After these meetings, a con-
sensus set of annotations was produced for each PubMed abstract.
The ﬁnal Phase of the annotation process consisted of the ﬁrst
author going over all annotated documents and ensuring that
annotations were consistent across different abstracts and differ-
ent annotation sets. Lists of problematic annotations were pro-
duced and discussed in a ﬁnal annotators meeting, where all
discrepancies were resolved.
2.1.4. Annotation consistency evaluation metrics
We measured the annotators’ agreement after Phase I of the
annotation process. One way to measure the agreement between
two annotators is to measure their observed agreement on the
sample of annotated items. We measured agreement by computing
the F-measure between each pair of annotators that worked on the
same set of documents, as also noted in [26,39].
Agreement statistics are measured for each annotator pair. First
an F-measure agreement average is computed for all annotated
mentions in each PMID document in the shared annotation set.
Then the average over all PubMed documents of the shared set is
Fig. 1. Screenshot of our annotation software PubTator displaying the differences in annotation for two annotators at the end of Phase I.
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statistic is computed over all annotation sets that they shared.
2.2. Disease normalization methods
As an attempt to demonstrate its utility, we used our corpus as a
gold standard for benchmarking three different disease normaliza-
tion methods. The methods are used at an ab initio setting, where
both disease mention recognition and disease concept normaliza-
tion is performed. The methods performances are compared after
the normalization step. The NCBI disease corpus has also been used
for the development of a successful machine learning method for
disease name normalization, DNorm.
2.2.1. Dictionary look-up method
The traditional dictionary look-up performs exact matching
using terms in the vocabulary. This method matches the disease
name as it appears in the terminology and is therefore not robust
against term variability that was not foreseen during creation of
the lexicon. In addition, precision may be affected by ambiguous
or nested terms. To address those issues, we used Norm, from
the SPECIALIST lexical tools (http://lexsrv3.nlm.nih.gov/SPECIAL-
IST/index.html) to preprocess all disease names in the MEDIC lex-
icon including their synonyms. The normalized names and
synonyms were then applied to the strings and substrings of the
PMID documents in the NCBI disease corpus. When a textual string
in the PubMed abstracts in the NCBI testing set was mapped by
Norm to a disease mention in the MEDIC lexicon, that disease men-
tion is grounded to the corresponding MEDIC concept. The results
of this string matching method are reported as Norm in Section 3.
2.2.2. MetaMap processing
MetaMap [12] is the state-of-the-art natural language process-
ing tool for identifying UMLS Metathesaurus concepts in biomedi-
cal text. MetaMap splits the given input text into sentences, andthe set of sentences into phrases. For each phrase, MetaMap iden-
tiﬁes possible mappings based on lexical look-up and on variants
associating a score to each one of them. MetaMap identiﬁes several
possible mappings in each phrase and several candidates for each
one.
In this work, the text of PubMed citations in the NCBI disease
corpus, title and abstract, was run through the MetaMap Web tool
to identify all UMLS concepts in that text. Next, for each PMID, the
list of UMLS concept identiﬁers (CUIs) found by MetaMap was
mapped to their corresponding MeSH descriptors and OMIM iden-
tiﬁers. The resulting MeSH and OMIM identiﬁers were further ﬁl-
tered in two ways:
a. Only concepts associated with the disorder Semantic Group
were kept (i.e., concepts linked to these semantic types:
Acquired Abnormality, Anatomical Abnormality, Congenital
Abnormality, Cell or Molecular Dysfunction, Disease or Syn-
drome, Experimental Model of Disease, Injury or Poisoning,
Mental or Behavioral Dysfunction, Neoplastic Process, Path-
ologic Function, Sign or Symptom).
b. Only concepts in MEDIC were kept.
The ﬁltered set of MeSH and OMIM ids was evaluated against
the gold-standard annotations. Results are reported as MetaMap
results.
2.2.3. The Inference Method
The Inference Method is our prior work [9] on disease normal-
ization. Our results (F-measure: 79%) showed that this method
linked disease mentions to their corresponding medical vocabulary
entry with high precision. The core of the Inference Method was
built as a combination of several string matching rules that
mapped the annotated strings to the names of the diseases as listed
in the standard disease dictionary and/or their accompanying list
of synonyms. In addition, this method successfully exploited the
Table 2
NCBI disease corpus as training, development and testing sets for disease name
recognition.
Corpus characteristics Training
set
Development
set
Test
set
Whole
corpus
PubMed citations 593 100 100 793
Total disease
mentions
5145 787 960 6892
Unique disease
mentions
1710 368 427 2136
Unique concept ID 670 176 203 790
Fig. 3. Distribution of mentions and concepts in the corpus documents.
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in the same abstract. Once the abbreviation was resolved, the
knowledge of the mapping of the long form of the disease was used
to infer the mapping of the abbreviated mention. Gold standard
data is essential in building a successful normalization method.
The Inference Method was designed and reﬁned on a manually
annotated set of PubMed abstract sentences which reﬂected the
consensus annotation agreement of the EBI disease corpus[13]
and the AZDC disease corpus [11] (the only available data at the
time). Because the original annotations used UMLS as a resource,
UMLS concepts were converted to MeSH descriptors. Because the
textual mentions were missing from the original annotations, NCBI
disease corpus annotations were consulted to build the Inference
Method gold standard set. In this work, this method was used both
for generating NCBI disease corpus pre-annotations, and as a dis-
ease name normalization benchmark. To evaluate its performance
in an ab initio setting, ﬁrst BANNER [40] was applied on each Pub-
Med abstract for disease mention recognition, and then, the Infer-
ence Method was applied for disease name normalization.
3. Results
3.1. Inter-annotator agreement
Overall, we achieved a high agreement between annotators as
shown in Fig. 2 where each dot represents a comparison score be-
tween two annotators for one or more shared sets. The red dotted
line shows the average F-score agreement over all annotator pairs.
3.2. NCBI disease corpus statistics
NCBI disease corpus contains 793 fully annotated PubMed cita-
tions. This constitutes more than 6 K sentences, of which more
than half contain disease names. For benchmarking purposes, the
entire corpus was split into three subsets (training, development,
and test sets). As shown in Table 2, there are 2136 unique disease
mentions total, mapped to 790 unique database identiﬁers.
3.2.1. Distribution of annotated concepts per PubMed citation
On average, the NCBI disease corpus contains 5.08 disease men-
tions and 3.28 disease concepts per PubMed abstract. Detailed
breakdown of the number of unique mentions and concepts per
abstract is shown in Fig. 3. As shown, while the proportion of arti-
cles that contain only a single disease mention is merely 5%, the
proportion of articles linking to a single disease concept is higherFig. 2. Inter-annotator annotation agreement for the disease name normalization
task. The red dotted line shows the average F-score among all annotator pairs.than 26%. The reason is that there are many ways in mentioning
the same concept as manifested in Fig. 2. Incidentally, the concept
Genetic Diseases, Inborn [D030342] is the most frequent concept,
appearing in 113 different documents, while ‘‘cancer’’ is the most
frequent mention, appearing in 44 documents. The top 10 most
common disease mentions and disease concepts in the NCBI dis-
ease corpus are listed in Table 3.3.2.2. Coverage of MeSH and OMIM concepts
One novel aspect of this work is the fact that disease mentions
are linked to MeSH descriptors and/or OMIM identiﬁers. Out of 790
unique disease name normalizations, 698 (or 88%) are composed of
MeSH identiﬁers, and 92 (or 12%) contain an OMIM identiﬁer. TheTable 3
The most common disease mentions and disease concepts in the NCBI disease corpus,
with the corresponding number of abstracts they appear in.
Disease mentions (number
of abstracts)
Disease concepts (number of abstracts)
Cancer (44) D030342 – Genetic Diseases, Inborn (113)
Tumor (43) D009369 – Neoplasms (112)
Breast cancer (41) D061325 – Hereditary Breast and Ovarian
Cancer Syndrome (52)
DM (39) D001943 – Breast Neoplasms (46)
Myotonic dystrophy (35) D009223 – Myotonic Dystrophy (42)
G6PD deﬁciency (33) D005955 – Glucosephosphate Dehydrogenase
Deﬁciency (36)
DMD (33) D020388 – Muscular Dystrophy, Duchenne
(33)
Ataxia-telangiectasia (30) D011125 – Adenomatous Polyposis Coli (33)
APC (29) D001260 – Ataxia Telangiectasia (31)
Duchene muscular
dystrophy (27)
D010051 – Ovarian Neoplasms (27)
Table 4
Distribution of MeSH versus OMIM concepts.
Set MeSH
(unique)
OMIM
(total)
Annotated concepts
(unique)
Training 1512 (599) 198 (71) 1710 (670)
Development 316 (153) 52 (23) 368 (176)
Testing 378 (182) 49 (21) 427 (203)
Fig. 4. Distribution of disease name concepts with respect to the number of disease
mention strings that map to them.
Table 5
Benchmarking results of three disease normalization methods (micro-average).
Method Precision Recall F-measure
Dictionary look-up 0.218 0.685 0.331
MetaMap (semantic type ﬁltering) 0.475 0.644 0.547
MetaMap (MEDIC ﬁltering) 0.502 0.665 0.572
Inference Method 0.533 0.662 0.591
Table 6
Benchmarking results of three disease normalization methods (macro-average).
Method Precision Recall F-measure
Dictionary look-up 0.213 0.718 0.316
MetaMap (semantic type ﬁltering) 0.495 0.679 0.541
MetaMap (MEDIC ﬁltering) 0.510 0.702 0.559
Inference Method 0.597 0.731 0.637
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of the NCBI disease corpus is given in Table 4.
3.2.3. NCBI disease corpus has low ambiguity level
Finally, 719 (or 91%) of the 790 normalizations in the NCBI dis-
ease corpus are single concepts, either MeSH descriptors or OMIM
identiﬁers, 52 normalized concepts are composite mappings corre-
sponding to composite mentions, and only 24 need combination of
multiple concepts to describe the given disease mentions. Typical
examples of composite mappings are: pancreatic, basal cell,
colonic, breast, and cervical carcinomas (D010190
|D002280|D015179|D001943|D002583), Prader-Willi and Angel-
man syndromes (D011218|D017204), syndromic and non-syn-
dromic hearing loss (D034381|C537845), and non-familial breast
and ovarian cancers (D001943|D010051), etc. Examples of multi-
ple concept mappings are: autosomal recessive cardiodegenerative
and neurodegenerative disease (Genetic Diseases, Inborn
[D030342] + Neurodegenerative Diseases [D019636]), chorioreti-
nal dystrophy (Choroid Diseases [D015862] + Retinal Dystrophies
[D058499]), and ochronotic arthropathy(Joint Diseases
[D007592] + Ochronosis [D009794]).
3.2.4. One-to-one and many-to-one mappings to disease concepts in
the NCBI disease corpus
On average, a disease concept is associated with 2.74 disease
mentions in our corpus. As pointed out above, the NCBI disease
corpus is a resource with low-ambiguity level. For example, more
than half of the disease concepts in the NCBI disease corpus are
associated with a disease mention in a one-to-one mapping as
shown in Fig. 4. In our analysis, we found the following outliers:
Twenty-six disease concepts, or 3.3%, are associated with more
than 10 textually different disease mentions, with the maximum
being 57. Of these, only four concepts correspond to general dis-
ease classes: Genetic Diseases, Inborn [D030342] (‘‘genetic dis-
ease,’’ ‘‘recessively inherited condition’’), Neoplasms [D009369]
(‘‘cancer,’’ ‘‘sporadic tumors,’’ ‘‘bilateral and multifocal tumours’’),Immunologic Deﬁciency Syndromes [D007153] and Demyelinating
Diseases [D003711]. These may represent opportunities for further
vocabulary reﬁnement. The rest either correspond to speciﬁc
diseases such as speciﬁc enzyme deﬁciencies, such as Glucose-
phosphate Dehydrogenase Deﬁciency [D005955] (‘‘Glucose 6-
phosphate dehydrogenase deﬁciency,’’ ‘‘G6PD-deﬁcient,’’ ‘‘deﬁ-
ciency of G6PD’’), or speciﬁc cancers, including Hereditary Breast
and Ovarian Cancer Syndrome [D061325] (‘‘hereditary human
breast and ovarian cancer,’’ ‘‘inherited breast-ovarian cancer,’’
‘‘breast-ovarian cancer-family syndrome’’). These variabilities re-
ﬂect the productivity of language; recognizing these cases would
likely beneﬁt more from the development of better machine learn-
ing methods for disease recognition.
3.3. Benchmarking results for disease normalization methods on NCBI
disease corpus
In this section we present the assessment of disease name res-
olution from natural language text. In this task we want to link the
diseases with the appropriate concept in the MEDIC dictionary. The
evaluation consists in comparing the annotations produced by
each one of the methods with the annotations in the gold standard
(the NCBI disease corpus – test dataset). We report the standard
measures: precision, recall and F-measure at two granularity levels
(micro-average and macro-average). Micro-average evaluation
takes into consideration all predictions (unique) for each of the
100 PubMed citations that constitute the NCBI test dataset, and
compares them with the whole set of (unique) gold-standard
annotations. Macro-average evaluation ﬁrst computes the stan-
dard measures for each PubMed citation in the test dataset, and
then takes a global average over all the values (see results in Tables
5 and 6).
3.4. Error analysis for the disease name normalization with the NCBI
disease corpus
We performed an error analysis to help illustrate the relative
strengths and weaknesses of the different methods we employed.
We randomly selected 20 PubMed abstracts from the testing data-
set and reviewed the output results of our methods. All methods
experienced both false positives and false negatives due to term
variations not present in the lexicon, such as matching mention
‘‘neuromuscular disorder’’ to concept Neuromuscular Diseases
[D009468]. Dictionary lookup, in addition, suffered from a large
number of false positives due to matches from non-entity tokens,
such as ‘‘be,’’ ‘‘all,’’ and ‘‘feed,’’ to an abbreviation listed as a disease
synonym. This type of error was successfully ignored by MetaMap
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noun phrase, and by the Inference Method due to the speciﬁc han-
dling of abbreviated disease terms. Very general disease terms
such as disorder, dysfunction, etc., were not considered interesting
per our annotation guidelines and therefore were not included in
annotation. MetaMap results, although ﬁltered accordingly to ex-
clude such terms, still produced a few remaining artifacts such as
‘‘nonsense mutation’’ and ‘‘suffering’’. Another problem found in
the MetaMap results were mappings such as ‘‘deﬁciency’’ (from
‘‘deﬁciency of the ninth component of complement’’) to concept
Malnutrition [D044342]. The Inference Method provided an
improvement by linking these mentions to concepts listed within
the MeSH subtree of Immunologic Deﬁciency Syndromes
[D007153], although mappings to the wrong component number
were often observed. Another common type of error for the Infer-
ence Method was its tendency to map to the most speciﬁc concept,
for example the mention ‘‘cerebellar degeneration’’ was mapped to
concept Subacute Cerebellar Degeneration [C535352], instead of
Cerebellar Degeneration, Primary [D013132]. The Inference Meth-
od was able to handle more term variation than other methods, but
also experienced both false positives and false negatives due to
named entity recognition errors (such as missing the ‘‘14’’ in
‘‘paternal uniparental disomy 14’’).
Finally, as can be seen in Tables 5 and 6, the dictionary method
provides strong recall compared to the other methods, but also the
lowest precision. Using MEDIC to restrict the MetaMap results to
diseases provides both higher precision and higher recall than
restricting the results using the UMLS semantic types referring to
disease. The recall increase is caused by the inclusion of some con-
cepts in MEDIC, which are excluded from the set of UMLS semantic
types such as ‘‘Findings’’ used for ﬁltering to maintain reasonable
precision. The increase in precision is also expected as we are
restricting MetaMap results to the more focused domain by using
MEDIC. The Inference Method provides the highest precision, high-
est F-measure and the highest macro-averaged recall so far.4. Discussion
Despite the efforts in the biomedical research community and
the named-entity recognition challenge tasks organized in the bio-
medical domain (BioCreative, BioNLP, TREC, i2b2, etc.), disease
name recognition research has lacked in the development of com-
petitive machine-learning methods due to the unavailability of
suitably-sized gold-standard corpora. The NCBI disease corpus is
signiﬁcantly larger than the other available corpora with disease
mention and/or concept annotations.
In addition, when we compare the NCBI disease corpus with the
Jimeno et al., [13] and Leaman et al. [11] corpora we can identify
several substantial differences:
1. The Jimeno et al. corpus does not have mention level anno-
tation, and consists of only 856 PubMed sentences. It is
important to have both mention and concept level annota-
tion for purposes of building better quality recognition
methods.
2. The Leaman et al. corpus, while providing mention-level
annotation for 2783 PubMed sentences, consists of con-
cept level annotations to the most speciﬁc concept. This
leads to several inconsistencies, for example:
Cancer, cancers is found normalized to these concepts:
‘‘C0206663 – Neuroecodermal tumor’’, ‘‘C0006826 – malignant
neoplasms’’, ‘‘C1306459 – primary malignant neoplasm’’,
‘‘C0009402 – colorectal carcinoma’’, ‘‘C1527249 – colorectal can-
cer’’, ‘‘C0476089 – endometrial carcinoma’’, etc.3. Both previous corpora consist of selected PubMed sen-
tences, while the NCBI disease corpus contains whole
abstract annotations. We can see this difference in the
annotation of abbreviated disease names, and their map-
ping to the correct concept. We have studied this issue
in [9,22]. Our ﬁndings indicated that whole-document
annotations improve the ability to automatically identify
the correct concepts, in particular for abbreviated
disease names, which occur frequently in biomedical
literature.
Finally, the disease normalization methods results reported in
this paper and in DNorm [22] show that the NCBI disease corpus
is a suitable resource of gold-standard data to build better, more
accurate models for disease name recognition.
4.1. Choosing a terminology resource
Several terminological resources are available that provide dis-
ease terms. Amongst the most used resources are the Medical Sub-
ject Headings (MeSH), the National Cancer Institute (NCI)
thesaurus (http://www.cancer.gov/), SNOMED CT (http://
www.ihtsdo.org/) and the UMLS National Library of Medicine
UMLS resource that encloses the whole medical language termi-
nology into a single source. Primarily, each of these has a different
scope, and none of them has been designed to meet text mining
needs. Hence, the need for a useful resource for building more pre-
cise tools for disease name recognition is still unmet.
Previous corporahaveusedUMLSas abackbone tonormalizedis-
ease mentions [11,13]. While UMLS Metathesaurus is the broadest
resource of medical concepts, disease concepts correspond to only
a small subset of UMLS, namely the 12 semantic types that comprise
the Disorder group. The latest release of UMLS combines 136 source
vocabularies, with a resulting set of approximately 3 million (dis-
tinct) concepts. If we counted only the concepts comprising the 12
semantic types of the Disorder group — creating smaller and hence
more useful views of large terminology resources has also been sug-
gested by other studies in the literature, for example in [41] — we
would still count more than 540,000 distinct concepts.
SNOMED CT [42] was developed to enable a consistent way to
index clinical data and structure medical records. At 66,000 con-
cepts the SNOMED disorder branch may offer the right degree of
granularity which would be very useful for mining the clinical as-
pects of disease. An enrichment of the disease mentions in the
NCBI disease corpus with SNOMED terms could certainly make
the NCBI disease corpus more valuable for clinical applications.
However for the present this remains as future work.
The MEDIC disease lexicon [23] is a manually curated
resource that associates a MeSH descriptor from the ‘‘Diseases’’
category, and/or a genetic disorder identiﬁer from the OMIM
database to disease names found in PubMed literature. This col-
lection, at 10,000 entries, created a sufﬁcient combination for our
purposes, especially considering that neither MeSH nor OMIM
have licensing restrictions. In addition, all PubMed abstracts un-
dergo MeSH terminology indexing. Therefore, linking the disease
mention in PubMed abstracts with the corresponding MeSH/
OMIM identiﬁers would allow for easy integration with these
other NLM resources. Our work, which in a sense may serve as
the ﬁrst real life evaluation of MEDIC, shows that MEDIC
provides sufﬁcient coverage for the disease concepts found in
PubMed citations, making this the right environment for disease
name normalization for such purposes.
Other possible terminology resources that could be considered
for such purposes are the Disease Ontology [43] and the Human
Phenotype Ontology [44]. A future work that links MeSH/OMIM
ids in the NCBI disease corpus with these other terminologies
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and protein functions. Another important detail to consider is
the right level of annotation with the terminology terms. Recent
research efforts on large-scale community-wide assessment of
protein function annotation [45] illustrate the importance of
annotation and the use of the appropriate ontology for both anno-
tation and evaluation of computational methods. A computational
method that only reports highly speciﬁc terminology terms is
typically penalized in recall, while a method that only reports
the most general ontology terms would have higher recall but
its results would not be very useful in practice. Achieving the
right balance is important and should be investigated both from
the evaluation point of view and form the annotation point of
view.4.1.1. Mapping disease mentions to disease concepts
Our annotation results revealed some limitations of using the
MEDIC disease vocabulary. First, a handful of disease concepts
were discovered that were not included in MEDIC. For those, we
decided to include the appropriate OMIM identiﬁers (as explained
in Section 2.1.2, guideline 8).
Next, certain diseasementionswere found to not be easily repre-
sented using the standard categorizations. Thus we allowed multi-
ple concept normalization. Multiple concept normalization was
used for composite disease mentions such as ‘‘colorectal and endo-
metrial cancers’’ ?MeSH: D010051|D016889. Of interest is the
fact that the composite mention ‘‘hereditary breast and ovarian
cancer syndrome’’ has a special MeSH descriptor: D061325, and
therefore there is noneed formultiple conceptnormalizationMeSH:
D001943 (breast cancer)|D010051 (ovarian cancer). Multiple con-
cept normalizationwas also used for providing a correct representa-
tion of a disease mention, when normalization to a single disease
concept did not sufﬁciently convey the meaning intended by the
authors, for example, ‘‘inherited muscular disease’’ is normalized
to MeSH: D009468 – Neuromuscular Diseases + D030342 – Genetic
Diseases, Inborn.
Our annotation work also pointed out at certain future direc-
tions for standard vocabulary development. For example, for some
disease entries as shown in Fig. 3, the large number of disease
mentions mapped to the same concept suggests that perhaps a
more reﬁned classiﬁcation is needed. We also identiﬁed disease
nuances described in the literature which were lost during map-
ping, due to the lack of speciﬁcities and or detailed categorizations
of diseases:
Ex: ‘‘PRAD1 mRNA is abundantly expressed in seven of seven
centrocytic lymphomas (Kiel classiﬁcation), in contrast to 13 clo-
sely related but noncentrocytic lymphomas.’’ The current map-
ping is: centrocytic lymphomas ? Mantle cell lymphoma
[MESH:D020522], noncentrocytic lymphomas ? Lymphoma
[MESH:D008223] since there exists no disjoint classiﬁcation of
lymphoma in MeSH or OMIM, into centrocytic versus
noncentrocytic.
‘‘We explored the 30 Dutch kindredswell known to the DutchX-
ALD/AMN Study Group and phenotyped 77 male patients: 35 (46%)
had adrenomyeloneuropathy (AMN) and 24 (31%) childhood
cerebral ALD (CCALD) or adolescent cerebral ALD (AdolCALD).’’
The current mapping is Adrenoleukodystrophy [MeSH:D000326]
since the speciﬁc categories identiﬁed in the article are not present
in the standard nomenclature. Note that, this is a normal and ex-
pected observation. Disease research articles are expected to report
variability, distinctions and subtypes of known diseases. With time,
certain distinctions will enter the vocabulary and get listed in the
terminology resources. Regardless, a successful disease recognition
program is expected to recognize all the mentions listed in the arti-
cle and all the concepts they correspond to.4.2. Disease name normalization as opposed to gene name
normalization
The logic employed to determine whether two entities should
be considered synonymous is not the same for genes and diseases.
Genes can typically be sequenced and traced to a speciﬁc genomic
location, providing a signiﬁcant degree of precision to the decision
of whether or not two genes (or gene products) represent the same
entity. Diseases, on the other hand, are always deﬁned descrip-
tively, through a collection of attributes, including symptoms, sys-
tems affected, references to disease processes, or to the disease
etiology. Since disease deﬁnitions require some judgment to apply,
there is therefore a signiﬁcant amount of ambiguity present in any
discussion of disease. The resulting variation is reﬂected in both
disease names and the mentions used to refer to diseases.
Notably, none of the normalization methods we applied
achieved performance comparable to systems developed for gene
normalization tasks. Gene normalization is better studied, partially
due to the existence of appropriate corpora for system develop-
ment and evaluation, and also because shared tasks such as BioCre-
ative have consistently included a task involving gene
normalization. In addition, recent work in gene normalization
has demonstrated that machine learning techniques provide a
performance advantage if the necessary training data is available
[14–16]. We believe that the NCBI disease corpus, with the joint
annotation of mentions and concepts over the same text, will allow
exploration of similar machine learning techniques for disease
names, which were previously not possible. In this regard, the NCBI
disease corpus will provide a valuable resource to the text mining
researchers for the development of more capable, more powerful
system in the ﬁeld of disease name recognition.5. Conclusions
This work presents the NCBI disease corpus, a richly annotated
corpus with disease names and their corresponding MeSH and/or
OMIM identiﬁers. This resource contains 793 PubMed abstracts,
and lists 6892 disease mentions, which are linked to 790 unique
concepts, thus providing an important foundation for improving
the text-mining research on disease named entity recognition.
Our experiments demonstrated the feasibility of using the corpus
as the basis for training learning models in both named entity
identiﬁcation and concept recognition, and we expect these results
to serve as benchmark for other future methods. To facilitate future
benchmarking experiments, the corpus is also divided into train-
ing, development and testing sets.
The NCBI disease corpus contains annotations for all sen-
tences in a PubMed document (title and abstract), an important
aspect in facilitating development of complex information retrie-
val tasks that connect diseases to treatments, causes or other
types of information. This corpus provides annotation of disease
mentions in four major categories: Speciﬁc Disease (i.e., clear-
cell renal cell carcinoma), Disease Class (i.e., cystic kidney dis-
eases), Composite mentions (i.e., prostatic, pancreas, skin, and
lung cancer), and Modiﬁer (i.e., hereditary breast cancer families)
[21]. Disease normalization annotation guidelines were designed
with the goal of allowing ﬂexible matching to MeSH (diseases
branch) and OMIM concepts, while retaining the true meaning
of the speciﬁc mention. The current corpus was reviewed several
times by several annotators and describes a reﬁned scale of the
annotation categories. The NCBI corpus can act as a basis for the
development of more accurate machine learning systems for dis-
ease name recognition and normalization, as well as boost re-
search into other areas of biomedical knowledge discovery
pertaining to diseases.
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in XML, plain text and in the PubTator-compatible format. The
disease corpus website also includes detailed description of the
annotation process and the annotation guidelines.
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